Associated Papers
β-Human Chorionic Gonadotropin-Secreting Giant Cell Tumor of Bone in the Mandible: Case Report and Comprehensive Literature Review.
Flores-Hidalgo A et al.
Head and Neck Pathology, 2026
H3-3A gene mutation analysis in giant cell tumor of bone and its histologic mimics: A single institutional study from India.
Uppin SG et al.
Annals of Diagnostic Pathology, 2026
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
Nucleotide Substitution Biases in Related Cancer Driver Genes.
Khadre A et al.
International Journal of Molecular Sciences, 2025
Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis.
Salani F et al.
Esmo Open, 2025
Conventional (bone-type) giant cell tumor of the larynx: the first case with proven H3-3A: c.103G >T (p.Gly35Trp) mutation.
Laco J et al.
Virchows Archiv : an International Journal of Pathology, 2025
Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone: NCC-GCTB11-C1 and NCC-GCTB12-C1.
Adachi Y et al.
Human Cell, 2025
Genetics of urinary bladder paragangliomas: a multi-center study of a Chinese cohort.
Jiang J et al.
Journal of Endocrinological Investigation, 2025
Insights into the genetic landscape of pheochromocytomas and paragangliomas in a Brazilian cohort.
Fagundes GFC et al.
European Journal of Endocrinology, 2025
A Rare Pediatric Giant Cell Tumor of the Clivus Bone, H3.3 p.Gly35Trp-mutated: Case Report and Mini-review of the Literature.
Gaggero G et al.
Turkish Archives of Pediatrics, 2025
Genomic Insights Into High-Grade Infarct-Associated Bone Sarcomas.
Tvrdik T et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2024
GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.
Ikeuchi H et al.
Oncogene, 2024
H3.3-G34W in giant cell tumor of bone functionally aligns with the exon choice repressor hnRNPA1L2.
Lee E et al.
Cancer Gene Therapy, 2024
Osteosarcomas With Few Chromosomal Alterations or Adult Onset Are Genetically Heterogeneous.
Difilippo V et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology, 2024
Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment.
Zethoven M et al.
Nature Communications, 2022
Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases.
Yang L et al.
Annals of Diagnostic Pathology, 2022
Diagnostic Utility of Genetic and Immunohistochemical H3-3A Mutation Analysis in Giant Cell Tumour of Bone.
Wągrodzki M et al.
International Journal of Molecular Sciences, 2022
A Comprehensive Understanding of the Genomic Bone Tumor Landscape: A Multicenter Prospective Study.
Xie X et al.
Frontiers in Oncology, 2022
Mutational Profile and Potential Molecular Therapeutic Targets of Pheochromocytoma.
Ma X et al.
Frontiers in Endocrinology, 2022
A common classification framework for histone sequence alterations in tumours: an expert consensus proposal.
Leske H et al.
The Journal of Pathology, 2021
Electronic DNA Analysis of CSF Cell-free Tumor DNA to Quantify Multi-gene Molecular Response in Pediatric High-grade Glioma.
Bruzek AK et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2020
Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone.
Lutsik P et al.
Nature Communications, 2020
Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone.
Yoshida KI et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2019
[H3F3A mutated multicentric giant cell tumor of bone : A very rare primary bone disease].
Giesche JP et al.
Der Pathologe, 2018
The identification of H3F3A mutation in giant cell tumour of the clivus and the histological diagnostic algorithm of other clival lesions permit the differential diagnosis in this location.
Scotto di Carlo F et al.
Bmc Cancer, 2018
Detection of H3F3A p.G35W and p.G35R in giant cell tumor of bone by Allele Specific Locked Nucleic Acid quantitative PCR (ASLNAqPCR).
Gamberi G et al.
Pathology, Research and Practice, 2018
Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging.
Alrezk R et al.
Frontiers in Endocrinology, 2018
Highly recurrent H3F3A mutations with additional epigenetic regulator alterations in giant cell tumor of bone.
Ogura K et al.
Genes, Chromosomes & Cancer, 2017
Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone.
Righi A et al.
Human Pathology, 2017
H3F3 mutation status of giant cell tumors of the bone, chondroblastomas and their mimics: a combined high resolution melting and pyrosequencing approach.
Kervarrec T et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2017
Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas.
Toledo RA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
Girolami I et al.
Journal of Clinical Pathology, 2016
Bilateral Lung Metastases From a Phalangeal Giant Cell Tumor of Bone.
Orr A et al.
Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society, 0